Key Highlights for Investors:
- Intellia Therapeutics (NTLA, Financial) launches Phase III MAGNITUDE-2 trial for nexiguran ziclumeran (nex-z).
- Analysts' average price target suggests substantial upside potential.
- GuruFocus estimates indicate a significant projected fair value increase.
Intellia Therapeutics (NTLA) has embarked on an important milestone by initiating dosing in its Phase III MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z), targeting hereditary ATTR amyloidosis with polyneuropathy. This trial is crucial for validating the safety and efficacy observed in Phase I, encompassing around 50 participants.
Wall Street Analysts Forecast
The consensus among the 23 analysts offering one-year price targets for Intellia Therapeutics Inc (NTLA, Financial) averages at $43.78, with projections spanning a high estimate of $106.00 to a low of $8.00. This average target suggests a remarkable upside of 446.26% compared to the current trading price of $8.02. For more precise details, explore our Intellia Therapeutics Inc (NTLA) Forecast page.
Currently, the stock is rated "Outperform" by 28 brokerage firms, reflected in an average brokerage recommendation of 2.1. The rating scale ranges from 1, indicating "Strong Buy," to 5, representing "Sell." This favorable rating underscores positive sentiment toward the company's prospects.
Assessing GF Value Metrics
According to GuruFocus estimates, the projected GF Value for Intellia Therapeutics Inc (NTLA, Financial) over the next year stands at $28.51, implying a potential upside of 255.71% from the current stock price of $8.015. The GF Value metric combines historical trading multiples, past business growth, and future performance estimates to provide an intrinsic value that guides investment decisions. For further insights, please visit the Intellia Therapeutics Inc (NTLA) Summary page.
Keeping abreast of these forecasts and estimates is vital as they offer substantial insights into the potential trajectory and investment appeal of Intellia Therapeutics.
